Sinovac Biotech logo

SVA - Sinovac Biotech News Story

$6.47 0.0  0.0%

Last Trade - 22/02/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £191.1m
Position in Universe th / 6850

UPDATE 3-Sinopharm unit, CanSinoBIO apply in China for COVID-19 vaccines' public use approval

Wed 24th February, 2021 5:30am
(Recasts, adds detail on Sinopharm unit's vaccine)
    Feb 24 (Reuters) - A unit of China National Pharmaceutical
Group (Sinopharm) and CanSino Biologics Inc (CanSinoBIO)
 6185.HK  have applied for public use of their COVID-19 vaccines
in China, which if granted would mean China has four locally
developed approved vaccines. 
    While China has yet to approve vaccines developed by Western
drug makers, it has granted authorisation to domestic products
for use in select groups or by the wider public, which have also
gained ground in developing countries battling a surge in
coronavirus infections.
    Sinopharm affiliate Wuhan Institute Of Biological Products
said on Wednesday its vaccine has an efficacy rate of 72.51%
against the COVID-19 disease caused by the virus, citing interim
analysis of late-stage clinical trial data, without offering
more details.
    The vaccine has already been given to limited groups of
people at higher infection risk under an emergency vaccination
program started in July.
    It is one of two candidates from Sinopharm that have entered
Phase III clinical trials overseas.
    The other, developed by a Beijing-based subsidiary of
Sinopharm, received public use approval in December, following
months of emergency use among targeted groups such as medical
workers and state-owned company employees travelling abroad for
work.      
    In a separate filing on Wednesday, CanSinoBIO said interim
analysis of data from its multi-country trial showed its
candidate one-shot vaccine, known as Ad5-nCoV, had a success
rate of 68.83% at preventing all symptomatic disease and 95.47%
at preventing severe disease 14 days after vaccination.
    This fell to an efficacy rate of 65.28% at preventing all
symptomatic cases and 90.07% at preventing severe disease 28
days after a single dose.
    Ad5-nCoV has gained emergency use authorisation in Pakistan
and Mexico, and was cleared last year for use by Chinese
military personnel.
    China has given public use approval for a vaccine from
Sinovac Biotech  SVA.O  earlier this month, which is also being
used in mass inoculation drives in countries including
Indonesia, Turkey and Brazil.  
    These four Chinese vaccines can be stored at normal freezer
temperatures, making them a potentially attractive option to
many developing countries, which struggle to use rival products
such as vaccines from Pfizer and Moderna, which require much
colder temperatures for longer-term storage.
    China is exporting vaccines to 27 countries and providing
free doses to 53 countries, a foreign ministry spokesman said on
Tuesday.

 (Reporting by Anushka Trivedi in Bengaluru and Roxanne Liu in
Beijing; editing by Kim Coghill and Jason Neely)
 ((Anushka.Trivedi@thomsonreuters.com; +918061823241;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.